ITGAM and neoplasm: At day 9 post MC17-51 tumor injection, a time at which tumors had similar size in Shp2f/f and Shp2f/fLysMCre mice, we collected CD45+CD11b+Ly6ChiLy6G− monocytes and CD45+CD11b+Ly6CloLy6G+ neutrophils from the bone marrow of tumor-bearing Shp2f/fLysMCre mice, mixed them with an equal number of MC17-51 tumor cells and injected them subcutaneously into naïve wild-type (WT) mice30.